Mark Dunphy on Muck Rack

Mark Dunphy

  • Senior Associate, Bateman Agency
San Francisco
As seen in: MSN, The Daily Mirror, Boston.com, SFGate, Stuff.co.nz, Chron, The Boston Globe, San Francisco Chronicle, Houston Chronicle, The Lancet and
@AgencyBateman. Previously: @riffcitystrat, @ExpressNews, @BostonDotCom, @DailyHampGaz.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Doing business in Australia

|
By Mark Dunphy
| Smarter Lawcast with Hall & Wilcox
Podcasts29 Oct 2025 By Mark Dunphy, Jacqui Barrett and Ben Hamilton Our international experts explore all you need to know when doing business in Australia, including the Foreign Investment Board Review (FIRB) regime, employment and migration trends, impacts of new merger clearance rules, key legal risks for investors and more. Listen to full episodes of Smarter Lawcast with Hall & Wilcox on Spotify, Apple Podcasts, Castbox and Youtube Podcasts.
Open in Who Shared Issue with article?

2025/26 Storm Names Revealed

|
By Mark Dunphy
Met Éireann has unveiled the list of names for the 2025/26 storm season, which begins today and runs until 31 August 2026. The list was developed in partnership with the UK Met Office and the Netherlands’ KNMI, with each partner contributing seven names. This year, Met Éireann asked the Irish public to submit suggestions through a social media campaign. More than 10,000 names were received from 4,137 members of the public.
Open in Who Shared Issue with article?

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

|
By Salomon Tendler, Mark Dunphy, Matthew Agee, Joseph O'Donoghue
| The Lancet Verified
Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [89Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89) in patients with neuroendocrine-derived cancer. 89Zr]Zr-DFO-SC16.56.
Open in Who Shared Issue with article?
See all 1,714 licensed articles (2,436 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified